Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-001 in advanced solid tumors
NCT06249048Phase 2Recruiting
- Sponsor
- Strand Therapeutics
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Cytokines & Interferons, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of STX-001 in solid tumor (advanced stage), triple-negative breast cancer (TNBC), melanoma, sponsored by Strand Therapeutics. Started May 2024; status: recruiting.
02
Drugs
STX-001
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)melanoma
Beyond the preview
Go deeper on NCT06249048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249048.